Lb Pharmaceuticals (LBRX) Total Non-Current Liabilities (2024 - 2026)

Lb Pharmaceuticals' Total Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $13.6 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $13.6 million in Q1 2026; TTM through Mar 2026 was $13.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $10.3 million, down 9.22% from the prior year.
• Total Non-Current Liabilities improved to $13.6 million in Q1 2026 per LBRX's latest filing, from $10.3 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $13.6 million in Q1 2026 and bottomed at $9.6 million in Q3 2025.
• The 3-year median for Total Non-Current Liabilities is $10.8 million (2024), against an average of $11.2 million.
• Biggest YoY gain for Total Non-Current Liabilities was 9.22% in 2025; the steepest drop was 9.22% in 2025.
• Year by year, Total Non-Current Liabilities stood at $11.3 million in 2024, then slipped by 9.22% to $10.3 million in 2025, then soared by 32.73% to $13.6 million in 2026.
• Per Business Quant, the three latest LBRX Total Non-Current Liabilities figures stand at $13.6 million (Q1 2026), $10.3 million (Q4 2025), and $9.6 million (Q3 2025).